And that’s it for this week! Thank you for joining us. Be sure to check out the full #SYNTAX paper at https://t.co/y1U4aAMNOF and an amazing summary available at https://t.co/c02syUV3Bc. See you next week for #ThoracicThursday !
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Mar 2022 – Jun 2025Where it's discussed
-
News8 articles
-
X / Twitter5 posts
-
Blogs4 articles
-
Bluesky2 posts
-
YouTube2 videos
AI synopsis
What people are saying
The discussions demonstrate a balanced interest, as some users compare the article to earlier trials such as FAME 3, and others emphasize the importance of evidence-based practices in cardiology, using tone and references that suggest a meaningful exchange of ideas and respect for scientific debate.
Most discussions acknowledge the study's findings, emphasizing the continued relevance of CABG over PCI for severe coronary cases, though some express curiosity about the evolving evidence.
The discussions show a moderate level of interest, with some participants referencing related trials and the importance of evidence-based medicine, indicating engagement but not overwhelming curiosity.
Posts include references to specific studies like FAME 3 and solicit opinions from professionals, showing active engagement and critique rather than superficial comments.
The discussions highlight ongoing debates and reflections on clinical decision-making, suggesting that the article influences medical practice and scholarly conversations.
Abstract in brief
- This trial compared two treatments, PCI and CABG, for severe coronary artery disease, finding that PCI had higher rates of adverse events mainly due to more repeat procedures, leading to the conclusion that CABG remains the preferred standard for such cases.
- Both treatments showed similar rates of death and heart attacks after 12 months, but stroke was more common in patients who received CABG.
- Since the primary goal of the study was to show PCI was not worse than CABG, and it was found to be less effective in preventing repeat revascularization, CABG is still considered the best option for three-vessel or left main coronary artery disease.]
Top posts
Most liked on X and Bluesky@GarySingerMD @CardioNerds Not a cardio nerd, I remember during medicine training this was big, still applicable? https://t.co/VBQIH3ZCoq
@ADAlthousePhD @yudapearl @f2harrell @stephensenn @SMuellerLab I'm sorry to break it to you, but your ideation is wrong. In the spirit of the trialists' advice to causal theorists, please take the time to read how it was actually done, https://t.co/cNpxoqLohc https://t.co/ps1a0oGnvU then come back for an informed conversation.
Original article: https://t.co/Qv77XSCIb0
https://t.co/89qO7Ds6TL This lecture discusses the steps of evidence-based medicine #physiotherapy #physiotalk #evidence
"Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial." Publié ce jour dans @thelancet.bsky.social #MedSky #CardioSky www.thelancet.com/journals/lan...
All mentions
Evidence Based Medicine: Developing Clinical Questions and Applying Evidence in Practice
This video outlines the steps of Evidence Based Medicine including formulating a clinical question, finding the best evidence, critically appraising that evidence, and applying the results in practice.
COVID-19 Vaccine-Related Myocarditis and Cardiology Treatment Options
This week, we discuss COVID-19 vaccine-induced myocarditis, type 2 diabetes in children, optimal therapies for coronary artery disease, and alcohol's impact, highlighting recent research and clinical insights.
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With 3‐Vessel Coronary Artery Disease and Diabetes
"Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial." Publié ce jour dans @thelancet.bsky.social #MedSky #CardioSky www.thelancet.com/journals/lan...
And that’s it for this week! Thank you for joining us. Be sure to check out the full #SYNTAX paper at https://t.co/y1U4aAMNOF and an amazing summary available at https://t.co/c02syUV3Bc. See you next week for #ThoracicThursday !
Original article: https://t.co/Qv77XSCIb0
@GarySingerMD @CardioNerds Not a cardio nerd, I remember during medicine training this was big, still applicable? https://t.co/VBQIH3ZCoq
https://t.co/89qO7Ds6TL This lecture discusses the steps of evidence-based medicine #physiotherapy #physiotalk #evidence
@ADAlthousePhD @yudapearl @f2harrell @stephensenn @SMuellerLab I'm sorry to break it to you, but your ideation is wrong. In the spirit of the trialists' advice to causal theorists, please take the time to read how it was actually done, https://t.co/cNpxoqLohc https://t.co/ps1a0oGnvU then come back for an informed conversation.
T
RF
BS
LT